Clinical Trials Browser

Phase 3 × sugemalimab × 90 days × Clear all

NCT05700448 2026-02-05

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell